Anondita Medicare Ltd IPOANONDITA

The IPO opens on 22 Aug 2025 & closes on 26 Aug 2025.

Anondita Medicare Limited was incorporated as a Public Limited Company on March 12, 2024, with the Registrar of Companies, Central Registration Centre. Prior to this, Company business was run by current promoter, Mr. Anupam Ghosh, as a sole proprietorship under the name of M/s Anondita Healthcare (formerly M/s Healthcare Products) from year 1999 onwards. Company is a manufacturer of male condoms with a variety of flavors, with our flagship product marketed and sold under the brand 'COBRA'. It operate an installed production capacity of nearly 562 million condoms per annum, as per certificate issued by JP Sood, Chartered Engineer, dated November 21, 2024. Further, to follow sustainable production practices, Company uses CNG as a clean, environmentally friendly manufacturing fuel for its manufacturing plant situated at Sector 80, Gautam Budh Nagar, Noida, Uttar Pradesh. Promoter, Mr. Anupam Ghosh, started his journey into this industry in year 1999, by undertaking orders for the sale and packaging of condoms, via his proprietorship M/s Healthcare Products. Thereafter, in 2004 he set up his own condom manufacturing plant and started the manufacturing of condoms, under his proprietorship M/s Healthcare Products. Subsequently, in 2013, the name of the proprietorship was changed to M/s Anondita Healthcare. Later in 2024, the entire running business of this proprietorship, including all assets and liabilities, was transferred to the Company, Anondita Medicare Limited, vide Business Transfer Agreement dated April 01, 2024. The Company is planning an Initial Public Issue of 47,93,000 Equity Shares of the Face Value of Rs. 10/- each through Fresh Issue.

Anondita Medicare Ltd IPO will close on 26 Aug 2025.

<ul><li>Production capabilities.</li><li>Experienced management team and a motivated and efficient work force.</li><li>Cordial relations with our consumers.</li><li>Quality assurance and control.</li></ul>

<table class="table"> <thead> <tr> <th>S.No</th> <th>Promoters Name</th> <th>Pre Issue Shares</th> <th>Pre Issue Percentage</th> <th>Post Issue Shares</th> <th>Post Issue Percentage</th> </tr> </thead> <tbody> <tr> <td>1</td> <td>Anupam Ghosh</td> <td>11160591</td> <td>83.95</td> <td>11160591</td> <td>61.71</td> </tr> <tr> <td>2</td> <td>Sonia Ghosh</td> <td>2</td> <td>---</td> <td>2</td> <td>---</td> </tr> <tr> <td>3</td> <td>Reshant Ghosh</td> <td>2</td> <td>---</td> <td>2</td> <td>---</td> </tr> <tr> <td>4</td> <td>Anisha Ghosh</td> <td>2</td> <td>---</td> <td>2</td> <td>---</td> </tr> <tr> <td>5</td> <td>Madhvi Sharma</td> <td>2</td> <td>---</td> <td>2</td> <td>---</td> </tr> </tbody> </table>

<ul><li>The Company had negative cash flows from its operating, investing and financing activities in the past and may continue to have negative cash flows in the future. Sustained negative cash flow could impact the company growth and business.</li><li>The company depends on its top 10 customers for a significant portion of the company revenues. The loss of a major customer or significant reduction in demand from any of its major customers may adversely affect the company business, financial condition, results of operations and prospects.</li><li>The Company derives a significant portion of its revenue from government contracts and tenders for the supply of condoms under various public health initiatives. Participation in these tenders is subject to stringent regulatory compliance, quality standards, and other eligibility criteria. Any failures to meet the requirements enlisted in these tenders may result in the Company being debarred or disqualified from participating in future government tenders, which could have a material adverse effect on the company business, financial condition, and results of operations.</li><li>The company had obtained secured loans amounting to Rs. 2715.37 lakhs and unsecured loans amounting to Rs. 23.73 lakhs on a consolidated basis until March 31st 2025. As such any fluctuation in interest rates or change in repayment plan may adversely affect the Company's business. Moreover, unsecured loans could be recalled by Its lenders at any time, which may be earlier than anticipated, affecting the company repayment schedule.</li><li>Majority of assets, including both movable and immovable, have not yet been transferred under the name of the company.</li><li>The company Subsidiary, Anondita Healthcare and Rubber Products (India) Limited, have incurred losses in the past and may continue to do so in the future. Its may be required to fund the operations of the company Subsidiary in the future and Its investments in the company Subsidiary may eventually be written off, which could subject it to additional liabilities and could have an adverse effect on the Company's reputation, profitability and financial condition.</li><li>There is outstanding litigation pending against the company which, if determined adversely, could affect its business, results of operations and financial condition.</li><li>The company is dependent on third parties for the distribution and marketing of its products. If the company do not maintain and increase the number of its arrangements for the marketing and distribution of the company products, its business, financial condition and results of operations could be adversely affected.</li><li>Its top three states contribute its major revenue for the Financial year ended 31st March 2025, March 31st 2024, March 31st 2023. Any loss of business from one or more of these states may adversely affect the company revenues and profitability.</li><li>The company Registered Office and Corporate Office are shared with its promoter group companies and the same are not owned by it. Any termination of the relevant lease agreement in connection with such properties or its failure to pay annual lease rental, the same could adversely affect the company operations. If the company is required to vacate the same or if the company is unable to renew its current leases, due to any reason whatsoever, it may adversely affect the company business operations.</li><li>The company proposed capital expenditure relating to purchase of plant and machinery is subject to the risk of unanticipated delays in implementation and cost overruns.</li><li>The company's Directors do have any experience of listed companies.</li><li>The Company has entered into certain related party transactions in the past and may continue to do so in the future.</li><li>The company is may be required to enter into strategic partnerships and acquisitions in the future, in relation to its growth strategy. If the company unable to successfully identify and integrate acquisitions, its growth strategy and prospects may be adversely affected.</li><li>There may be potential conflict of interests between the Company, its Subsidiary, the company Group Companies and other venture or enterprises promoted by its promoter or directors (The Company Promoter Group Companies).</li><li>Any problems in the company quality control or manufacturing processes may damage its reputation, subject it to regulatory action and expose the company to litigation or other liabilities.</li><li>The company has limited operational experience and as such we may not be able to evaluate its business on the basis of past performance and compete in the industry due to limited history of the company.</li><li>The company operations requires significant amount of working capital for its smooth day to day operations and continuing growth of business. Any discontinuance or the company inability to procure adequate working capital timely and on favorable terms may have an adverse effect on its operations, profitability, and growth prospects.</li><li>The company may be unable to obtain and maintain the intellectual property rights for its brands or be able to prevent unauthorised use of trademarks obtained/ applied for by third parties, which may lead to the dilution of the company goodwill.</li><li>The company had certain delay in respect of payment of interest on loans to the, banks, FIs during the past three years. Defaulting on payments or delayed payments pf loans amount could lead to legal action, loss of collateral, and a damaged credit score, making it difficult for the company to secure financing in the future.</li><li>Any delay, interruption or reduction in the supply of the company raw materials from its third-party suppliers and manufacturers, or an increase in the costs of such raw materials, may adversely impact the pricing and supply of the company products and have an adverse effect on its business, financial condition, cash flows and results of operations.</li><li>The company is subject to extensive government regulations which are also subject to change. If its fail to comply with the applicable regulations prescribed by the governments and the relevant regulatory agencies, the company business, financial condition, cash flows and results of operations will be adversely affected.</li><li>The company is required to obtain, maintain or renew its statutory and regulatory approvals, licenses, and registrations to operate the company business.</li><li>The company inability to accurately forecast demand for the company products and manage its inventory may have an adverse effect on the company business, financial condition, cash flows and results of operations.</li><li>The Company has revalued its assets in the past.</li><li>Any disruption, slowdown or shutdown in the company manufacturing operations could adversely affect its business, financial condition, cash flows and results of operations.</li><li>Any failures to maintain and enhance, or any damage to, the company brands, product image or reputation could adversely affect the market recognition of, and trust in, its products.</li><li>The company may be required to make substantial investments in brand ambassadors, product design, marketing, advertising, community relations and employee training.</li><li>Certain Loans and Borrowings are reported in the financial statements of the company but have not actually been transferred in the name of the company.</li><li>If the company dose not successfully develop or commercialize new products in a timely manner, or if the products that its commercialize do not perform as expected, the company business, results of operations and financial condition may be adversely affected.</li><li>The Company is yet to place orders for the machineries for its proposed object of capital expenditure related to purchase of machinery, as specified in the Objects of the Issue. Any delay in placing orders, procurement of machineries etc. may delay the company implementation schedule and may also lead to increase in price of these plant & machineries, further affecting its revenue and profitability.</li><li>The company success depends on its ability to retain and attract qualified senior management and other key personnel, and if the company is not able to retain them or recruit additional qualified personnel, its may be unable to successfully develop the company business.</li><li>The pharmaceutical and consumer healthcare industries are intensely competitive and if the company unable to respond adequately to the increased competition or pricing pressure its expect to face, the company could lose market share and its revenues and profits could decline, which would in turn adversely affect the company business.</li><li>If any of the company product comes its to be damaged or is damaged during the course of use, it could cause serious reputational damage as well as product recalls, and the company business, financial condition, cash flows and results of operations could be adversely affected.</li><li>Reliance has been placed on declarations and affidavits furnished by the promoters and directors for details of their profiles included in this Red Herring Prospectus.</li><li>Improper handling of goods at the company facilities could damage its reputation and have an adverse effect on the company business, results of operations and financial condition</li><li>The company inability to deliver products in a timely manner may affect the company reputation and business prospects.</li><li>The company is exposed to government price controls which could negatively affect its results of operations.</li><li>The company is subject to the risk of loss due to fire, accidents and other hazards as the raw materials used in the company manufacturing process are highly flammable and hazardous.</li><li>The company is exposed to counter party credit risk and any delay in receiving payments or non-receipt of payments may adversely impact its business, financial condition, cash flows and results of operations.</li><li>The company may not be able to detect or prevent fraud or other misconduct committed by the company employees or third parties.</li><li>The company has contingent liabilities and capital commitments. the company financial condition could be adversely affected if any of these contingent liabilities or capital commitments materialize.</li><li>The company Promoters will be able to exercise significant influence and control over it after the IPO and may have interests that are different from or conflict with those of the company other shareholders.</li><li>Information relating to the installed manufacturing capacity, actual production and capacity utilization of the company manufacturing units included in this Red Herring Prospectus are based on various assumptions and estimates and future production and capacity may vary</li><li>The company insurance coverage in connection with the company business may not be adequate and may adversely affect its operations and profitability.</li><li>Certain Agreements, deeds, licenses, certificates and other assets may be in the previous name of the company, its has to update the name of our company in all the statutory approvals and certificates due to the conversion of the Company.</li><li>In addition to normal remuneration, other benefits and reimbursement of expenses, some of the company Directors (including its Promoters) are interested in the Company to the extent of their shareholding and dividend entitlement in the Company.</li><li>Any variation in the utilisation of the Net Proceeds would be subject to certain compliance requirements, including prior shareholders' approval.</li><li>The Company is subject to foreign exchange control regulations which can pose a risk of currency fluctuations.</li><li>The Company has not paid any dividends in the past 3 financials years and its ability to pay dividends in the future may be affected by any material adverse effect on the company future earnings, financial condition or cash flows.</li><li>Industry information included in this Red Herring Prospectus has been derived from industry reports from various websites. The reliability on the forecasts of the reports could be incorrect and would significantly impact the company operations.</li><li>The Company's future funding requirements, in the form of further issue of capital or other securities and/or loans that might be availed by it, may turn out to be prejudicial to the interest of the shareholders depending upon the terms and conditions on which they are raised.</li><li>The average cost of acquisition of Equity Shares by the company Promoters is lower than the issue price.</li><li>There are certain restrictions on daily movements in the price of Equity Shares, which may adversely affect a shareholder's ability to sell, or the price at which it can sell, Equity Shares at a particular point in time.</li><li>After this Issue, the price of the Equity Shares may be highly volatile, or an active trading market for the Equity Shares may not develop.</li><li>Market price of the company share will be decided by market forces and issue price of equity share may not be indicative of the market price of its share price after the issue.</li></ul>

The Issue type of Anondita Medicare Ltd is Book Building - SME.

The minimum application for shares of Anondita Medicare Ltd is 2000.

The total shares issue of Anondita Medicare Ltd is 4793000.

Initial public offering up to 47,93,000 equity shares of Rs. 10/- each ("equity shares") of Anondita Medicare Limited ("Anondita" or "AML" or the "company") for cash at a price of Rs. 145/- per equity share (the "issue price"), aggregating to Rs. 69.50 crores ("the issue"). Out of the issue, 2,70,000 equity shares aggregating to Rs. 3.92 crores will be reserved for subscription by market maker ("market maker reservation portion"). The issue less the market maker reservation portion i.e. issue of 45,23,000 equity shares of face value of Rs. 10/- each at an issue price of Rs. 145/- per equity share aggregating to Rs. 65.58 crores is hereinafter referred to as the "Net Issue". The issue and the net issue will constitute 26.50 % and 25.01 %, respectively of the post issue paid up equity share capital of the company.